<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01247090</url>
  </required_header>
  <id_info>
    <org_study_id>AAAE0454 - pilot</org_study_id>
    <nct_id>NCT01247090</nct_id>
  </id_info>
  <brief_title>Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease</brief_title>
  <official_title>Pilot Study of the Effect of Intradialytic Vasopressin Infusion on Chronic Blood Pressure Control in Hypertensive Patients With End Stage Renal Disease: A Program to Develop a Decisive, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The death rate of patients with endstage renal disease (ESRD) on dialysis each year is 20%,
      with diseases related to the heart and blood vessels causing about half. About 60% of
      patients on hemodialysis have high blood pressure, which is poorly controlled in most. Normal
      blood pressure in these patients greatly improves the chance of living. Increased fluid in
      the body and bloodstream is a major cause of hypertension in patients with ESRD. Fluid
      removal during hemodialysis is often limited by symptoms of low blood pressure during the
      procedure. Therefore the increase in fluid and related high blood pressure is ongoing for
      many of these patients. Arginine vasopressin (AVP) is a hormone naturally produced by the
      body which has little effect on blood pressure in healthy people, but acts as a powerful
      vasoconstrictor (narrows the blood vessels) when blood pressure is threatened. Recent studies
      have shown when there is too little AVP, patients are more likely to have low blood pressure
      during dialysis that limits fluid removal, an effect that can be reversed by giving these
      patients low doses of AVP. This phase II trial will find out which of two doses of AVP (.15
      or .30 mU kg-1 min-1), in combination with standard therapy, works best to change
      interdialytic 44-hour ambulatory systolic blood pressure after 2 weeks. Patients who enroll
      in this study will be divided into three groups. One group will be given a 0.15 mU kg-1 min-1
      dose of AVP at each dialysis session over a 2-week period; the second group will be given AVP
      0.3 mU kg-1 min-1 at the same interval; and a third group will be given normal saline
      (placebo) at the same interval. All patients will be closely monitored for side-effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot study originally enrolled a group of 12 subjects (4 subjects per arm) in order to
      demonstrate feasibility with the primary outcome measure, interdialytic 44-hour ambulatory
      systolic blood pressure. Data on the original subjects is complete and results are posted.

      The data from this study will be used to design and conduct additional study
      enrollment/extension (24 subjects) in order to make some initial statistical comparisons
      between groups, which will help establish greater confidence in our novel method for
      controlling blood pressure in dialysis patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2010</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Interdialytic 44-hour Ambulatory Systolic Blood Pressure Over a 2 Week Follow-up Period</measure>
    <time_frame>Baseline and Two Weeks</time_frame>
    <description>This is designed to measure if the administration of intradialytic AVP will result in change in systolic blood pressure.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hypertension</condition>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Group 1: Vasopressin - Very Low Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.15 mU per kg per minute</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Vasopressin - Low Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.30 mU per kg per minute</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No Dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasopressin - Very Low Dose</intervention_name>
    <description>Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.15 mU * 70 kg, or 10.5 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.</description>
    <arm_group_label>Group 1: Vasopressin - Very Low Dose</arm_group_label>
    <other_name>Vasopressin Injection</other_name>
    <other_name>USP (8-L arginine vasopressin)</other_name>
    <other_name>AVP</other_name>
    <other_name>Pitressin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasopressin - Low Dose</intervention_name>
    <description>Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.30 mU * 70 kg, or 21 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.</description>
    <arm_group_label>Group 2: Vasopressin - Low Dose</arm_group_label>
    <other_name>Vasopressin Injection</other_name>
    <other_name>USP (8-L arginine vasopressin)</other_name>
    <other_name>AVP</other_name>
    <other_name>Pitressin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Participants in Group 3 will receive an equal volume of normal saline (placebo) infusion during their standard thrice-weekly dialysis treatments.</description>
    <arm_group_label>Group 3: Placebo</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  End Stage Renal Disease on Hemodialysis greater than 3 months

          -  Hypertension (Predialysis systolic blood pressure (SBP) greater than 140 mmHg,
             averaged over preceding 6 dialysis treatments)

          -  Stable dry weight over preceding 6 dialysis treatments

        Exclusion Criteria:

          -  Age less than 18 years

          -  Clinically significant vascular disease*

          -  Predialysis systolic blood pressure (SBP) greater than 200 mmHg or diastolic blood
             pressure (BP) &gt;110

          -  Pregnancy

          -  Long QTc syndrome (an electrocardiogram (ECG) will be performed if unavailable within
             the last 3 months)

        Clinically significant vascular disease is defined as any of the following occurring in the
        preceding three months: angina, claudication, transient ischemic attack, myocardial
        infarction, cerebrovascular accident, or decompensated heart failure. Furthermore, patients
        will be excluded if they have any history of ischemic colitis or Raynaud's disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anjali Ganda, M.D., M.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 22, 2010</study_first_submitted>
  <study_first_submitted_qc>November 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2010</study_first_posted>
  <results_first_submitted>April 4, 2011</results_first_submitted>
  <results_first_submitted_qc>April 4, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 28, 2011</results_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>end stage renal disease</keyword>
  <keyword>vasopressin</keyword>
  <keyword>Arginine Vasopressin</keyword>
  <keyword>AVP</keyword>
  <keyword>Pitressin®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 27, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT01247090/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Very Low Dose</title>
          <description>Very Low Dose: Active Comparator 0.15 mU per kg per minute</description>
        </group>
        <group group_id="P2">
          <title>Low Dose</title>
          <description>Low Dose: Active Comparator 0.30 mU per kg per minute</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>No Dose - Placebo Comparator</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Very Low Dose</title>
          <description>Very Low Dose: Active Comparator 0.15 mU per kg per minute</description>
        </group>
        <group group_id="B2">
          <title>Low Dose</title>
          <description>Low Dose: Active Comparator 0.30 mU per kg per minute</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>No Dose - Placebo Comparator</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.0" spread="8.04"/>
                    <measurement group_id="B2" value="71.0" spread="8.98"/>
                    <measurement group_id="B3" value="72.3" spread="8.66"/>
                    <measurement group_id="B4" value="73" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Interdialytic 44-hour Ambulatory Systolic Blood Pressure Over a 2 Week Follow-up Period</title>
        <description>This is designed to measure if the administration of intradialytic AVP will result in change in systolic blood pressure.</description>
        <time_frame>Baseline and Two Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Very Low Dose</title>
            <description>Very Low Dose: Active Comparator 0.15 mU per kg per minute</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Low Dose: Active Comparator 0.30 mU per kg per minute</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>No Dose - Placebo Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Interdialytic 44-hour Ambulatory Systolic Blood Pressure Over a 2 Week Follow-up Period</title>
          <description>This is designed to measure if the administration of intradialytic AVP will result in change in systolic blood pressure.</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="8.6"/>
                    <measurement group_id="O2" value="-3.7" spread="27.0"/>
                    <measurement group_id="O3" value="-0.4" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Two weeks.</time_frame>
      <desc>Method of systematic assessment: Physician assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Very Low Dose</title>
          <description>Very Low Dose: Active Comparator 0.15 mU per kg per minute</description>
        </group>
        <group group_id="E2">
          <title>Low Dose</title>
          <description>Low Dose: Active Comparator 0.30 mU per kg per minute</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>No Dose - Placebo Comparator</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anjali Ganda, MD</name_or_title>
      <organization>Columbia University Medical Center</organization>
      <phone>617-835-3789</phone>
      <email>ag355@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

